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Syrian hamsterThe mechanisms implicated in prion infection and tissue distribution are not completely under-
stood. In this study we investigated the levels of 263K prions in brain and spleen of Syrian hamsters
few days after intra-peritoneal challenge. For this purpose we utilized the PMCA technology which
permits to detect as little as few PrPSc molecules. Our results show that peripherally administered
prions directly reach the brain, although at levels below the minimum necessary to produce disease.
PrPSc remains in the brain several days after administration suggesting inefﬁcient clearance or early
replication. Understanding the fate of the infectious agent after administration and its uptake in dif-
ferent organs and ﬂuids may provide useful information to develop strategies to minimize further
spreading of prion diseases.
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Transmissible Spongiform Encephalopathies (TSEs) are a group
of proteopathies affecting several mammalian species [1]. Creutz-
feldt–Jakob disease (CJD) is the most prevalent disease in humans
affecting one individual per million people every year [1,2]. Despite
their low incidence, TSEs have been extensively studied due to
their intriguing mechanisms of propagation and their zoonotic
transmission potential [3–6]. As of today, TSEs are the only group
of diseases transmitted by a protein-based infectious agent [7–9].
TSEs are characterized by long incubation periods followed by a
short clinical phase that invariably leads to death [4]. In order to
experimentally decrease these long incubation periods, intra-cere-
bral inoculations are used to assess infectivity in animal models.
However, peripheral routes of administration are more relevant
when assessing natural mechanisms of transmission. It is well doc-
umented that PrPSc accumulates in several peripheral tissues,
much before the appearance of the ﬁrst clinical signs [10,11].
Spleen and lymph nodes are important contributors to peripheral
prion replication as well as to the transport of the agent to the
brain, either by the vascular, sympathetic or parasympathetic sys-
tems [12,13]. Replication and accumulation of prions in peripheralorgans do not produce any important damage to the tissue and the
clinical disease is only manifested when they extensively accumu-
late in the brain.
The long incubation periods and the fact that peripheral tissues,
including blood, can harbor infectious quantities of prions [14–16]
is a major concern for public health [3]. Reports of disease trans-
mission by transfusion using blood from individuals silently incu-
bating variant Creutzfeldt–Jakob disease (vCJD) urge the
development of methods that can detect the infectious agent dur-
ing its long and silent incubation period [3,15,17]. Animal bioas-
says and cell-based prion replication systems can be used to
detect the infectious material. However, these assays take a long
time to be completed and are often limited to only a subset of prion
strains/animal species, reducing their applicability. In vitro assays
such as Protein Misfolding Cyclic Ampliﬁcation (PMCA, [8,18])
and Quaking Induced Conversion (QuIC, [19]) look promising as
effective techniques for the identiﬁcation of misfolded prions in
different organs and ﬂuids [20–22], even at pre-symptomatic
stages of the disease [11,23].
To understand the mechanism of prion propagation within the
body, it is important to study how PrPSc spreads and replicates in
different tissues and organs after peripheral challenge. The purpose
of this study was to analyze the tissue distribution and brain
uptake of infectious prions in experimental hamsters few days
after peripheral infection. Since the amount of prions in this organ
is presumably very low at this stage, we estimated PrPSc levels
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prions in this organ with the ones in spleen, where PrPSc replication
appears to occur at earlier stages [24].
2. Materials and methods
2.1. Samples
4 weeks old female Syrian Golden Hamsters (Harlan) were in-
tra-peritoneally (i.p.) injected with 75 lL of 10% brain homoge-
nates (prepared as previously explained [8]) from a symptomatic
263K infected hamster. Hamsters were sacriﬁced at 0 (30 min), 2,
4 and 9 days after injection (n = 5/group). Spleens and brains were
collected and stored at 80 C until use. All animal manipulations
were carried out in accordance to NIH regulations and approved by
the Animal Welfare Committee of the University of Texas Medical
School at Houston.
2.2. Preparation of tissue homogenates
Brain and spleen homogenates were prepared at 10% in phos-
phate saline buffer (PBS, MP Biomedicals, cat. No. 1860454) with
a protease inhibitor cocktail (Roche Diagnostics, cat. No. 11 697
498 001). After a brief centrifugation to eliminate debris (805 g
for 45 s in a Beckman-Coulter Allegra 25R centrifuge), supernatants
were used for Western blot (WB) analysis. To concentrate PrPSc and
remove tissue components that may interfere with PMCA, 500 lL
of sample were mixed with a sarkosyl (Fisher Bioreagents, cat.
No. BP234) solution prepared in PBS (ﬁnal concentration, 10%)
and centrifuged at 100000g for 1 h at 4 C [25]. Supernatants
were discarded and PBS was added to the pellets (without resus-
pension) in order to dilute out traces of detergent. Samples were
centrifuged again at 100,000 g for 30 min at 4 C. Final pellets were
resuspended in 100 lL of normal hamster brain homogenate pre-
pared at 10% in Conversion Buffer (PMCA substrate, 150 mM NaCl
and 1% Triton X-100 in PBS) [8,26] and submitted to PMCA.
2.3. Protein Misfolding Cyclic Ampliﬁcation and Western blotting
Spleen and brain pellets resuspended in PMCA substrate were
submitted to 96 PMCA cycles. Serial rounds were performed by
mixing 10 lL of the resulting sample with 90 lL of fresh PMCA
substrate. Tissue homogenates and PMCA products were treated
with 50 lg/mL of Proteinase K (PK, Sigma–Aldrich, cat. No.
P2308) for 1 h at 37 C. PK digestion was stopped by adding LDS
loading buffer (Invitrogen, cat. No. NP0007) and heating for
5 min at 100 C. Samples were fractionated by SDS–PAGE and
transferred into nitrocellulose membranes. Membranes were
probed with 3F4 antibody (Covance, cat. No. SIG-39600) and signal
observed by using ECL Plus detection system (GE Healthcare, cat.
No. RPN2132) as recommended by the manufacturer.3. Results
In order to analyze the distribution of PrPSc at early stages after
infection we i.p. injected 263K prions in Syrian hamsters and
brains and spleens were collected at several days (0, 2, 4 and 9)
post-injection. Crude brain homogenates taken at these stages
did not show any detectable amount of PrP27–30 after conventional
PK digestion andWestern blotting (Fig. 1a). For comparison, Fig. 1b
shows the PrP27–30 levels typically observed in the brain of a symp-
tomatic 263K hamster inoculated with the same amount of prions
by the same route.
Previous reports showed that prions can rapidly distribute in
several tissues, including the brain, after intra-venous (i.v.)injection [27,28]. In order to investigate the brain uptake of prions
soon after exposure, we assessed the presence of PrPSc in this organ
by PMCA [29]. This technique has been proven to detect as little as
one particle of infectious prions [30]. Our results showed that we
were able to detect PrPSc in brains after 5 rounds of PMCA in a frac-
tion of animals sacriﬁced at 2, 4 and 9 days after treatment (Fig. 2).
Only 1 out of 5 animals was positive 2 days after inoculation
whereas no animals showed to be positive at day 0 (sacriﬁced
30 min after injection). The fraction of positive animals increased
to 2/5 in 4 and 9 days post-challenge. This data suggest that after
reaching the brain, PrPSc is not efﬁciently cleared. We analyzed
the detection limit of our method by performing dilutions of
263K brain homogenates from a symptomatic hamster (Fig. 3a).
According to this data we estimated that the PrPSc levels in the
brain of PMCA-positive animals were equivalent to a brain dilution
of 5  1011 of a symptomatic hamster. It is important to highlight
that control brain homogenates submitted to PMCA ampliﬁcation
in the absence of PrPSc seeds did not show any positive signal
(Fig. 3b).
It is well documented that spleen is one of the most important
peripheral organs in terms of prion replication. PrPSc generated in
this tissue acts as a reservoir of infectious units that later on invade
the central nervous system [31]. However, it is suggested that pri-
ons replicated in the periphery reach the brain only at later stages
of their incubation periods. Using PMCA we detected the presence
of PrPSc in spleen of some animals just after 3 PMCA rounds at the
same day of injection (Fig. 4). PrPSc detection was lower, but still
positive, 2 days after infection (2/5 animals), but decreased at
4 days. At 9 days after challenge no PrPSc was detectable at the
3rd PMCA round. At the 5th PMCA round the tendency was even
clearer: at 0 and 4 days post inoculation PrPSc was detected in
the spleen of 4/5 animals, whereas a lower proportion of animals
was detected at 9 days post inoculation (2/5). These results suggest
that prions in spleen at these early time points correspond to the
original inoculum injected, which is progressively cleared over
time from this organ. Altogether, this data suggest that PrPSc de-
tected in spleen and brain at these short time points correspond
to the original inoculum administered.
It is important to highlight that there appears to be a high ani-
mal-to-animal variability in PrPSc detection both in spleen and
brain. This variability is not due to the PMCA reaction, since anal-
ysis of replicate samples in PMCA containing the same amount of
diluted PrPSc showed little variability. This data indicate that dis-
tinct animals handle prions differently at the moment of infection.
4. Discussion
In this study we investigated the uptake of infectious prions in
spleens and brains at early stages after peripheral challenge. The
relatively rapid detection of prions in the brain suggests that PrPSc
can directly reach this organ after inoculation. These results are in
agreement with our previous observations using puriﬁed, radiola-
beled PrPSc, which clearly demonstrated that prions can cross the
blood–brain barrier to reach the brain parenchyma [27,28,32].
According to our ampliﬁcation control shown in Fig. 3, the amount
of prions we detected in brain few days after inoculation is equiv-
alent to a 5  1011 brain dilution of a symptomatic 263K infected
hamster. Previous reports estimated that 1LD50 of 263K prions
after i.c. infection is equivalent to a brain dilution of 1109
[8], although this estimation can vary between samples [33,34].
The higher infectious brain dilution for i.c inoculations has been
determined in the same range for several other prion strains such
as RML, ME7 and Hyper-TME as tested by in vivo and cell based as-
says [35–37]. The last infectious dilutions for peripheral routes are
considerably lower than the ones described for direct i.c. inocula-
tions [35]. Thus, our results indicate that the quantity of prions
ab
Fig. 1. Absence of detectable amounts of PrP27–30 in brain homogenates of 263K injected hamsters shortly after inoculation. (a) Brains from hamsters sacriﬁced at 0, 2, 4 and
9 days after i.p. infection with 263K prions were homogenized and analyzed by PK treatment and WB as explained in methods. All samples were negative for PrP27–30. (b)
Brain serial dilutions from a symptomatic 263K i.p. infected hamster analyzed in the same way as in (a). NBH correspond to brain homogenates from healthy hamsters (no PK
treated) used as a control of electrophoretic mobility. Horizontal lines at the right of each gel represent the position of a 36KDa (a) or 26KDa (b) molecular weight standard.
Solid vertical lines depict separation of different gels. Numbers at top of panel (b) represent dilutions of brain homogenate.
Fig. 2. Detection of PrPSc by PMCA in brains of 263K infected hamsters sacriﬁced few days after inoculation. Brain extracts were precipitated by centrifugation in the presence
of sarkosyl, pellet resuspended in normal brain homogenates from healthy hamsters and submitted to serial PMCA. After PMCA, samples were PK treated and analyzed as
described in methods. NBH correspond to brain homogenates from healthy hamsters (no PK treated) used as a control of electrophoretic mobility. Horizontal lines at the right
of each gel represent the position of a 36KDa molecular weight marker. Solid vertical lines between different gels indicate blot splicing.
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is around 100 times lower than the ones necessary to produce
disease.
Importantly, PrPSc was detectable in brain and spleen only in a
fraction of the animals injected. This may explain the animal-to-
animal variation in terms of incubation periods when infectivity
bioassays are performed, especially when animals are inoculated
with highly diluted material or are injected by peripheral routes
(i.p., per os). This individual variation could result from dissimilar
amounts of prions successfully reaching the brain, distinct rates of
prion replication or different rates of clearance between animals,
among others. Further research may clarify whether the inter-indi-
vidual variability observed in our results has a long term repercus-
sion in disease. Nevertheless, the amount of misfolded prions inanimals having detectable levels of PrPSc was below infectious lev-
els. This indicates that the direct uptake of prions to the brain may
not be responsible for disease transmission, which would likely re-
quire peripheral replication of the agent followed by neuroinva-
sion, probably through peripheral nerves.
It is very well documented that several tissues other than brain
can carry prion infectivity, albeit in lower titers. Among them, one
of the most important and best characterized is the spleen [31].
According to our results, the amount of PrPSc detected in this organ
at early time points after infection is approximately 100000 times
higher than in brains. It is important to note that 10% spleen
homogenates from a 263K symptomatic hamster do not show
any signal of PK resistant PrP by conventional WB (data not
shown). In fact, it has been reported that spleens from 263K
a b
Fig. 3. Serial PMCA of brain dilutions from a 263K symptomatic hamster. (a) 10-fold dilutions from a brain of a 263K symptomatic hamster were submitted to PMCA in order
to assess the detection limit in each PMCA round. After the procedure, samples were PK digested and analyzed by WB. The WB shown here is representative of 4 independent
assays. (b) Serial PMCA of normal brain homogenates (without PrPSc seeds). NBH corresponds to brain homogenates from healthy hamsters (no PK treated) used as a control
of electrophoretic mobility. Horizontal lines at the right of each gel represent the position of a 36KDa molecular weight marker.
Fig. 4. Detection of PrPSc in spleens of 263K infected hamsters sacriﬁced at early time points after inoculation. Spleen homogenates taken at the indicated time points were
precipitated by centrifugation in the presence of sarkosyl, the pellet was resuspended in brain homogenate substrates and samples were submitted to serial PMCA assay.
Samples were PK treated after ampliﬁcation and analyzed by WB. NBH correspond to brain homogenates from healthy hamsters (no PK treated) used as a control of
electrophoretic mobility. Horizontal lines at the right of each gel represent the position of a 36KDa molecular weight marker. Solid vertical lines between gels indicate splicing
of different blots.
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less than brains [31]. In addition we observed that the presence of
prion seeds in spleen progressively decreased in time (Fig. 4). Thisdata suggest that the prions we are detecting in spleen at this early
time points correspond to the original inoculum that was adminis-
trated. Nevertheless, previous studies by animal bioassays have
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at early points during the incubation period, reaching plateau lev-
els much faster than those present later in the brain [31]. Our re-
sults are in agreement with a previous report showing that
infectivity is found in the spleen of 263K infected hamsters few
days after challenge [24].
It has been shown that PrPSc contains at least two population of
molecules, differing in their resistance to protease degradation [38]
and indeed it has been suggested that protease-sensitive PrPSc
might be the predominant species for some prion strains [39,40].
PMCA is able to detect with similar efﬁciency both protease-resis-
tant and protease-sensitive PrPSc forms [41]. Thus, we do not ex-
pect that determination of the amount of PrPSc present in a
sample by PMCA will be underestimated. Nevertheless, coupling
PMCA to detection methods that do not employ PK treatment
(i.e. sedimentation, thermolysin treatment, conformational depen-
dent immunoassay, etc.) could provide an alternative evaluation of
whether or not our results represent an underestimation of the to-
tal concentration of PrPSc present in the sample.
The ﬁndings presented in this study provide an initial descrip-
tion of the dynamic changes on PrPSc biodistribution soon after
peripheral infection. Our results indicate that PMCA is a suitable
technique to analyze the dynamics of prion replication during
the whole time course of in vivo prion infection, from challenge
to the symptomatic phase of the disease. Similar studies on various
prion strains and animal species (including humans) may have
important implications for understanding the mechanism of prion
formation, metabolism, clearance and transport. This information
would contribute to make informed decisions regarding risk
assessment and may lead to the development of novel strategies
for diagnosis and therapeutic intervention.
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